Upregulation of <scp>ADAMDEC1</scp> correlates with tumor progression and predicts poor prognosis in non‐small cell lung cancer (<scp>NSCLC</scp>) via the <scp>PI3K</scp>/<scp>AKT</scp> pathway

Zhu, Wei; Shi, Lin; Gong, Yaoqin; Zhuo, Lin; Wang, Siyun; Chen, Shaobing; Zhang, Bei; Ke, Bin

doi:10.1111/1759-7714.14354

Cited by 8 publications

(3 citation statements)

References 43 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant expression of PI3K signalling pathway is closely related to the process of tumourigenesis [ 34 ]. Lung cancer is the most lethal malignancy in the world, with non-small cell lung cancer (NSCLC) being the most commonly reported histological subtype [ 35 ]. According to reports, new oncogene changes have been discovered in NSCLC, including genetic changes in the PI3K pathway, and PIK3CA mutations in NSCLC may co-occur with epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homologue (KRAS) and anaplastic lymphoma kinase (ALK) mutations [ 36 , 37 ].…”

Section: Resultsmentioning

confidence: 99%

Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition

Wang

et al. 2023

IJMS

View full text Add to dashboard Cite

Aberrant expression of the phosphatidylinositol 3-kinase (PI3K) signalling pathway is often associated with tumourigenesis, progression and poor prognosis. Hence, PI3K inhibitors have attracted significant interest for the treatment of cancer. In this study, a series of new 6-(imidazo[1,2-a]pyridin-6-yl)quinazoline derivatives were designed, synthesized and characterized by 1H NMR, 13C NMR and HRMS spectra analyses. In the in vitro anticancer assay, most of the synthetic compounds showed submicromolar inhibitory activity against various tumour cell lines, among which 13k is the most potent compound with IC50 values ranging from 0.09 μΜ to 0.43 μΜ against all the tested cell lines. Moreover, 13k induced cell cycle arrest at G2/M phase and cell apoptosis of HCC827 cells by inhibition of PI3Kα with an IC50 value of 1.94 nM. These results suggested that compound 13k might serve as a lead compound for the development of PI3Kα inhibitor.

show abstract

Section: Resultsmentioning

confidence: 99%

Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition

Wang

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Various biomarkers for diagnosis and prognosis have been identified for NSCLC using the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, such as ADAM-like decysin-1 ( ADAMDEC1 ), 8 long non-coding RNASEH1-AS1 , 9 sialic acid binding Ig-like lectin 15 ( Siglec15 ), 10 lysine acetyltransferase 2B ( KAT2B ), 11 and Erb-b2 receptor tyrosine kinase 4 ( ERBB4 ). 12 Moreover, many gene signatures have been constructed to predict prognosis and therapeutic response for NSCLC, such as RNA-binding proteins related signature, 13 telomere length-related gene signature, 14 ferroptosis-related long non-coding RNAs signature, 15 immune microenvironment signature, 16 neutrophil extracellular traps-related lncRNA signature, 17 and glycolysis-related gene signature.…”

Section: Introductionmentioning

confidence: 99%

IER5L is a Prognostic Biomarker in Pan-Cancer Analysis and Correlates with Immune Infiltration and Immune Molecules in Non-Small Cell Lung Cancer

Chen,

He,

Miao

et al. 2023

IJGM

View full text Add to dashboard Cite

Purpose Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases. Immediate early response 5 like ( IER5L ) plays crucial roles in progression and prognosis for several tumors, but its role in NSCLC remains unclear. Patients and Methods Gene expression and mutation profiles, DNA methylation data, and clinical information for cancers were downloaded from multiple databases. Relative expression, prognostic value, and correlation with disease progression of IER5L were analyzed in multiple cancers, including NSCLC. Upstream mechanisms were explored using a transcriptional network. Functional enrichment analysis, protein–protein interaction network, and gene set enrichment analysis were applied to study downstream mechanisms. Correlations of IER5L with immune infiltration, immune molecules, methylation status, and tumor mutation burden (TMB) were analyzed using R language. Finally, quantitative polymerase chain reaction (qPCR) and single-cell RNA sequencing (scRNA seq) analysis were performed to validate IER5L expression in NSCLC. Results Pan-cancer analysis displayed that IER5L expression was upregulated in multiple cancers and was associated with disease prognosis and progression, including NSCLC, which was validated using qPCR. scRNA seq analysis showed that multiple cells had increased IER5L expression. An EGR1 -hsa-miR-8075- IER5L network was constructed for NSCLC. A total of 191 DEGs were identified between the two IER5L groups, which were significantly enriched in biological process of action potential, sodium ion transport, and regulation of membrane potential. Increased IER5L expression was primarily enriched in cell cycle, NOTCH signaling pathway, and oxidative phosphorylation pathway, and was correlated with increased regulatory T cells and neutrophils, elevated levels of immune molecules, and higher TMB. Conclusion Our findings show that increased IER5L expression was correlated with progression and prognosis in multiple cancers as well as with immune infiltration and immune molecules in NSCLC. Thus, IER5L is a prognostic biomarker in multiple cancers and may correlate with immunotherapeutic response in NSCLC.

show abstract

“…For central nervous system tumors, it was found that ADAMDEC1 expression level was significantly higher than the control group in either enamel epithelial craniopharyngioma or squamous papillary craniopharyngioma. ADAMDEC1 is rarely expressed in grade I and grade II gliomas, but highly expressed in grade III and grade IV gliomas ( 26 ). Based on the important roles that ADAMDEC1 played in other cancers, this study investigated the contribution and prognostic signature of ADAMDEC1 in glioma.…”

Section: Introductionmentioning

confidence: 99%

ADAMDEC1 accelerates GBM progression via activation of the MMP2-related pathway

Wang

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The ADAM (a disintegrin and metalloprotease) gene-related family including ADAM, ADAMTS, and ADAM-like decysin-1 has been reported to play an important role in the pathogenesis of multiple diseases, including cancers (lung cancer, gliomas, colorectal cancer, and gastrointestinal cancer). However, its biological role in gliomas remains largely unknown. Here, we aimed to investigate the biological functions and potential mechanism of ADAMDEC1 in gliomas. The mRNA and protein expression levels of ADAMDEC1 were upregulated in glioma tissues and cell lines. ADAMDEC1 showed a phenomenon of “abundance and disappear” expression in gliomas and normal tissues in that the higher the expression of ADAMDEC1 presented, the higher the malignancy of gliomas and the worse the prognosis. High expression of ADAMDEC1 was associated with immune response. Knockdown of ADAMDEC1 could decrease the proliferation and colony-forming ability of LN229 cells, whereas ADAMDEC1 overexpression has opposite effects in LN229 cells in vitro. Furthermore, we identified that ADAMDEC1 accelerates GBM progression via the activation of the MMP2 pathway. In the present study, we found that the expression levels of ADAMDEC1 were significantly elevated compared with other ADAMs by analyzing the expression levels of ADAM family proteins in gliomas. This suggests that ADAMDEC1 has potential as a glioma clinical marker and immunotherapy target.

show abstract

Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non‐small cell lung cancer (NSCLC) via the PI3K/AKT pathway

Cited by 8 publications

References 43 publications

Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition

Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition

IER5L is a Prognostic Biomarker in Pan-Cancer Analysis and Correlates with Immune Infiltration and Immune Molecules in Non-Small Cell Lung Cancer

ADAMDEC1 accelerates GBM progression via activation of the MMP2-related pathway

Contact Info

Product

Resources

About